Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016

Bowles, Erin J. Aiello; Ramin, Cody; Buist, Diana S.M.; Feigelson, Heather Spencer; Weinmann, Sheila; Veiga, Lene H.S.; Bodelón, Clara; Curtis, Rochelle E.; Vo, Jacqueline B; González, Amy Berrington de; Gierach, Gretchen L.

doi:10.1007/s10549-022-06561-z

Cited by 8 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In women who underwent chemotherapy, Black women were less likely to initiate endocrine therapy within 12 months (aHR 0.67, 95% CI 0.56-0.80); in contrast, no difference was detected in women who did not undergo chemotherapy (aHR 0.96, 95% CI 0.76-1.21). Of note, studies that included women with insurance either through the Kaiser Permanente integrated healthcare system or Medicare found that Black women were still less likely to initiate endocrine therapy within 12 months of diagnosis [62][63][64] (Table 3). Thus, having insurance may not be the only barrier to endocrine therapy.…”

Section: Endocrine Therapymentioning

confidence: 99%

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Lovejoy

Shriver

Haricharan

et al. 2023

IJERPH

View full text Add to dashboard Cite

Black women in the US have significantly higher breast cancer mortality than White women. Within biomarker-defined tumor subtypes, disparate outcomes seem to be limited to women with hormone receptor positive and HER2 negative (HR+/HER2−) breast cancer, a subtype usually associated with favorable prognosis. In this review, we present data from an array of studies that demonstrate significantly higher mortality in Black compared to White women with HR+/HER2-breast cancer and contrast these data to studies from integrated healthcare systems that failed to find survival differences. Then, we describe factors, both biological and non-biological, that may contribute to disparate survival in Black women.

show abstract

Section: Endocrine Therapymentioning

confidence: 99%

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Lovejoy

Shriver

Haricharan

et al. 2023

IJERPH

View full text Add to dashboard Cite

show abstract

“…Less use of ET among patients with in situ BC may have played a role in the higher risk observed in this subgroup. National rates of ET initiation are approximately 37% among patients with hormone receptor–positive ductal carcinoma in situ aged 15 to 39 years at primary diagnosis, which are much lower than the 94% ET initiation rate among young patients with invasive BC . In the present study, the small numbers of patients with in situ BC taking ET and with invasive BC not taking ET precluded our ability to assess this variable.…”

Section: Discussionmentioning

confidence: 99%

Second Primary Breast Cancer in Young Breast Cancer Survivors

Brantley,

Rosenberg,

Collins

et al. 2024

JAMA Oncol

View full text Add to dashboard Cite

ImportanceAmong women diagnosed with primary breast cancer (BC) at or younger than age 40 years, prior data suggest that their risk of a second primary BC (SPBC) is higher than that of women who are older when they develop a first primary BC.ObjectiveTo estimate cumulative incidence and characterize risk factors of SPBC among young patients with BC.Design, Setting, and ParticipantsParticipants were enrolled in the Young Women’s Breast Cancer Study, a prospective study of 1297 women aged 40 years or younger who were diagnosed with stage 0 to III BC from August 2006 to June 2015. Demographic, genetic testing, treatment, and outcome data were collected by patient surveys and medical record review. A time-to-event analysis was used to account for competing risks when determining cumulative incidence of SPBC, and Fine-Gray subdistribution hazard models were used to evaluate associations between clinical factors and SPBC risk. Data were analyzed from January to May 2023.Main Outcomes and MeasuresThe 5- and 10- year cumulative incidence of SPBC.ResultsIn all, 685 women with stage 0 to III BC (mean [SD] age at primary BC diagnosis, 36 [4] years) who underwent unilateral mastectomy or lumpectomy as the primary surgery for BC were included in the analysis. Over a median (IQR) follow-up of 10.0 (7.4-12.1) years, 17 patients (2.5%) developed an SPBC; 2 of these patients had cancer in the ipsilateral breast after lumpectomy. The median (IQR) time from primary BC diagnosis to SPBC was 4.2 (3.3-5.6) years. Among 577 women who underwent genetic testing, the 10-year risk of SPBC was 2.2% for women who did not carry a pathogenic variant (12 of 544) and 8.9% for carriers of a pathogenic variant (3 of 33). In multivariate analyses, the risk of SPBC was higher among PV carriers vs noncarriers (subdistribution hazard ratio [sHR], 5.27; 95% CI, 1.43-19.43) and women with primary in situ BC vs invasive BC (sHR, 5.61; 95% CI, 1.52-20.70).ConclusionsFindings of this cohort study suggest that young BC survivors without a germline pathogenic variant have a low risk of developing a SPBC in the first 10 years after diagnosis. Findings from germline genetic testing may inform treatment decision-making and follow-up care considerations in this population.

show abstract

Radiotherapy, chemotherapy, and heart disease

Sioka

2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016

Cited by 8 publications

References 66 publications

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer

Second Primary Breast Cancer in Young Breast Cancer Survivors

Radiotherapy, chemotherapy, and heart disease

Contact Info

Product

Resources

About